http://www.migueljara.com/2012/10/25/italia-suiza-y-austria-prohiben-la-venta-de-vacunas-contra-la-gripe-de-novartis/
Italia, Suiza, Austria y España han prohibido la venta de vacunas contra la gripe de la compañía farmacéutica suiza Novartis. Pueden existir problemas de seguridad en las mismas… que se suman a su manifiesta inutilidad.
Se sugiere leer estos textos. http://debovacunarme.blogspot.com/2012/11/virus-de-la-influenza-cobran-10-muertes.html http://debovacunarme.blogspot.com/2012/07/guillain-barre-fiebre-reumatica.html
Gobierno de España ordena la retirada de dos vacunas contra la gripe de empresa farmacéutica suiza
Archivo AFP
El Gobierno español decidió este jueves retirar de la venta dos vacunas contra la gripe fabricadas por el gigante farmacéutico suizo Novartis, convirtiéndose en el quinto país europeo en hacerlo tras Italia, Suiza, Austria y Alemania.
España "en colaboración con la Agencia Europea de Medicamentos y otras autoridades sanitarias europeas, informa de la inmovilización de todos los ejemplares de las vacunas antigripales estacionales Chiromas y Chiroflu", informó la Agencia Española de Medicamentos y Productos Sanitarios.
Esta retirada es debida "a la presencia de partículas flotantes blancas en las jeringas precargadas de algunos lotes de las mencionadas vacunas", precisó la agencia en su página web.
Update on seasonal influenza vaccines produced by Novartis Vaccines
European Medicines Agency supports Members States in coordinating action
A number of European Union (EU) Member States have halted the use, as a precautionary measure, of some anti-influenza vaccines manufactured by Novartis Vaccines, because of a suspected quality defect.
The Italian Medicines Agency (AIFA) was first informed of the suspected quality defect by the manufacturer (Novartis Vaccines) located in Italy. The Italian authorities took prompt precautionary action and AIFA alerted all other Member States, the European Commission and the European Medicines Agency using the established mechanisms.
These regulatory actions are precautionary, since so far there is no indication that this suspected quality defect has any impact on the safety or efficacy of the vaccines in question.
The European Medicines Agency has no formal legal role in this case, as the products are nationally authorised, but is taking a supporting role by bringing expertise from the network together to assist AIFA and the authorities in the other Member States.
AIFA is taking the lead on behalf of the EU in investigating the suspected quality defect in order to determine whether it affects the safety and efficacy of these vaccines, and whether the affected batches should be permanently removed from the market. The suspected defect involves the aggregation of proteins that are a normal part of the vaccines.
All Member States will evaluate the impact of the potential unavailability of the batches in question on their seasonal influenza vaccination programmes, which are an important public-health activity at this time of year.
The Agency and the Member States continue to monitor the situation.
No hay comentarios:
Publicar un comentario